FDA Authorizes Use Of AstraZeneca's Accurin AZD2811 In Clinical Trials

(RTTNews) - BIND Therapeutics Inc. (BIND) announced the U.S. FDA has authorized the use of AstraZeneca's Accurin AZD2811 in clinical trials under an investigational new drug application.

BIND Therapeutics is collaborating with AstraZeneca on the development of AZD2811, an Aurora B Kinase inhibitor that has been shown to be active in both solid and hematological tumors in preclinical models. AstraZeneca is responsible for clinical development and commercialization and BIND is responsible for conducting clinical manufacturing through at least the end of phase 2 clinical trials.

The companies anticipate enrolling patients in a phase 1 clinical trial with AZD2811 in the fourth quarter of the current year. BIND Therapeutics will earn a $4 million milestone payment upon first dosing a patient in a phase 1 clinical trial with AZD2811.